In conclusion, the risk of developing colitis should be accounted in patients treated with BRAF and MEK inhibitors, as it represents an uncommon adverse event with the potential to evolve into life-threating conditions, such as intestinal perforation. The gene discussed is BRAF; the disease is colitis.